TITLE

Constipation, Cardiovascular Disease, and the Connection

AUTHOR(S)
Gupta, Rahul
PUB. DATE
September 2011
SOURCE
Internal Medicine Alert;9/29/2011, Vol. 33 Issue 18, p137
SOURCE TYPE
Periodical
DOC. TYPE
Abstract
ABSTRACT
An abstract of the article "Constipation and risk of cardiovascular disease among postmenopausal women," by Salmoirago-Blotcher and colleagues is presented.
ACCESSION #
66387039

 

Related Articles

  • Constipation a simple clue to heart problems.  // Clinical Advisor;Aug2011, Vol. 14 Issue 8, p25 

    The article focuses on the result of a study conducted by Elena Salmoirago-Blotcher, medical doctor (MD), and her associates which states that constipation can be a marker for cardiovascular risk factors and increase cardiovascular risk in older women.

  • DRINKWATER ON EMPTY STOMACH. Ramrakhiani, Urmilla // Woman's Era;Jan2013, Vol. 40 Issue 938, p268 

    The article offers information on the use of water for treatment of several diseases including diabetes, constipation and gastric disorders. It also focuses on the methods for treating these diseases with the help of water. It suggests that one should not eat or drink anything for 45 minutes...

  • GI relief may come sooner than later for patients with chronic noncancer pain. Thompson, Cheryl A. // American Journal of Health-System Pharmacy;7/15/2014, Vol. 71 Issue 14, p1153 

    The article focuses on developments in chronic noncancer pain treatment, as addressed by advisers at a U.S. Food and Drug Administration (FDA) meeting held in Silver Spring, Maryland from June 11 to 12, 2014. Topics discussed include the cardiovascular safety hazard found on the drug alvimopan...

  • Role of prucalopride, a serotonin (5-HT4) receptor agonist, for the treatment of chronic constipation. Wong, Banny S.; Manabe, Noriaki; Camilleri, Michael // Clinical & Experimental Gastroenterology;2010, Vol. 3, p49 

    Constipation affects up to a quarter of the population in developed countries and is associated with poor quality of life and significant economic burden. Many patients with chronic constipation are dissatisfied with current therapy due to lack of long-term efficacy or side effects. Previous...

  • Oral administration of Bifidobacterium longum in a gastro-resistant seamless capsule decreases serum phosphate levels in patients receiving haemodialysis. Ogawa, Tetsuya; Shimada, Mikiko; Nagano, Nobuo; Ito, Kyoko; Ando, Tetsuo; Shimomura, Yohnosuke; Ando, Yoshitaka; Otsuka, Kuniaki // Clinical Kidney Journal;Aug2012, Vol. 5 Issue 4, p373 

    The article focuses on the oral administration of Bifidobacterium longum when gastro-resistant seamless capsule decreases phosphate levels in patients who are receiving haemodialysis (HD). It says that hyperphosphataemia is recognized as a risk factor for mortality and cardiovascular disease in...

  • Fabry disease — A challenge for diagnosis and treatment. VINTILA, Vlad; ENESCU, Oana // Maedica - a Journal of Clinical Medicine;2008, Vol. 3 Issue 4, p270 

    The article presents information on Fabry disease, a genetically inherited lysosomal storage disease which is characterized by intracellular and plasmatic accumulation of glycosphingolipids. The gene responsible for the disease is located on the X chromosome, due to which it has an X-linked...

  • Baobab Fruit Powder as a wholesome Food Ingredient. Fernsebner, Gabriele; Spaeth, Martin A. // Nutraceuticals Now;Spring2014, p50 

    The article discusses the benefits of Baobab fruit which contains soft, powdery pulp and kidney-shaped seeds. It mentions that Baobab fruit is rich in fibre and helpful in preventing constipation and maintaining health body-weight. It highlights that the fruit is effective in prevention of many...

  • Naloxegol Phase III Win Muted by FDA's CV Stance. Powers, Marie // BioWorld Today;11/13/2012, Vol. 23 Issue 221, p1 

    This article discusses the impact of the U.S. Food and Drug Administration's (FDA) stance toward additional cardiovascular (CV) safety trials for drugs in the class on the positive results of two Phase III studies and a safety extension trial of naloxegol (NKTR-118) in noncancer-related pain and...

  • All Eyes on FDA Safety Guidance. Powers, Marie // BioWorld Today;11/13/2012, Vol. 23 Issue 221, p5 

    This article discusses the impact of the U.S. Food and Drug Administration's (FDA) stance toward additional cardiovascular (CV) safety trials for drugs in the class on the positive results of two Phase III studies and a safety extension trial of naloxegol (NKTR-118) in noncancer-related pain and...

  • News in brief.  // Food Engineering & Ingredients;Nov2010, Vol. 35 Issue 4, p31 

    The article offers world news briefs related to food science. Studies find no correlation between intake of dairy products and increased risk of cardiovascular disease, citing that drinking three glasses of milk per day will reduce the risk of having such disease. Several studies find high risk...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics